Back to all Current clinical trials
Back to all Current clinical trials
FAME 1 Eye research study - A new treatment for retinopathy in type 1 diabetes
Type 1 diabetes with eye changes (retinopathy)
Fenofibrate has proved to slow the development of diabetic retinopathy and need for laser surgery for people with type 2 diabetes. The purpose of this study is to test whether Fenofibrate is also safe and effective in reducing retinopathy for people with type 1 diabetes.
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 3 Drug TrialLate stage studies conducted to confirm efficacy and safety of investigational therapies in large patient populations prior to introduction to clinical practice.
- Registry listing
Trial contact details
-
Contact person
Yvonne Gautam
What you need to know
Who can take part?
- People with type 1 diabetes.
- Those aged 18 years or over
- People with at least one eye with mild non-proliferative diabetic eye disease (retinopathy)
What is involved for you?
- vital signs taken (blood pressure, heart rate), height, weight
- electro cardiograms (ECGs)
- simple tests of foot sensation
- eye tests and photos taken
- blood and urine samples
- questionnaires
Trial dates
This trial is accepting participants until June 2024.
All research clinical trials news
-
News
Celebrating Excellence: Mater’s 2024 Publication of the Year Winners
-
News
Study aims to fight Inflammatory Bowel Disease with Aussie seafood
-
News
PhD student secures fellowship to pioneer mRNA vaccine for rare blood disorder
-
News
Clinical trials give hope to current and future breast cancer patients